English
简体中文
繁體中文
客服热线:400-1616-289
登录
注册
会议论文
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis
Wu, Yi-Long; Zhou, Qing; Wang, Jie; Yu, Yan; Xing, Ligang; Wang, Ying; Cheng, Ying; Pan, Yueyin; Fan, Yun; Shi, Jianhua; Zhang, Guojun; Cui, Jiuwei; Zhou, Jianying; Song, Yong; Zhuang, Wu; Ma, Zhiyong; Hu, Yanping; Li, Gaofeng; Dong, Xiaorong; Ahn, Myung-Ju
广东省人民医院; 华中科技大学; 吉林大学; 南方医科大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 中国医学科学院; 6; 1
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
2023-6-1
4
被引
16
阅读
引用
收藏
分享
相关
加载中…
文献加载失败,请重试
重试